Long-term complete remission of laryngeal Kaposi's sarcoma after palliative radiotherapy

2005 ◽  
Vol 2 (9) ◽  
pp. 473-477 ◽  
Author(s):  
Carmen Ares ◽  
Abdelkarim S Allal
Keyword(s):  
Complete Remission ◽  
Kaposi's Sarcoma ◽  
Palliative Radiotherapy ◽  
Kaposi’S Sarcoma

Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine.

1984 ◽  
Vol 2 (10) ◽  
pp. 1115-1120 ◽  
Author(s):  
L J Laubenstein ◽  
R L Krigel ◽  
C M Odajnyk ◽  
K B Hymes ◽  
A Friedman-Kien ◽  
...  
Keyword(s):  
Immune Deficiency ◽  
Complete Remission ◽  
Partial Remission ◽  
Kaposi's Sarcoma ◽  
Opportunistic Infections ◽  
Kaposi’S Sarcoma ◽  
Response Duration ◽  
Median Response ◽  
Stage Disease

An epidemic of disseminated Kaposi's sarcoma in male homosexuals has recently been described. Forty-one evaluable patients with epidemic Kaposi's sarcoma were treated with etoposide. The majority of these patients had early stage disease, no prior opportunistic infections, and no prior therapy. Twelve patients (30%) achieved complete remission, 19 (46%) partial remission, and ten (24%) no response. With follow-up time to 31 months, the median response duration is nine months. The median survival of patients with complete and partial remissions has not been reached. A combination of doxorubicin (Adriamycin, Adria Laboratories, Columbus, Ohio), bleomycin, and vinblastine (ABV) was used in 31 evaluable patients with epidemic Kaposi's sarcoma. The majority of these patients had late stage disease, prior opportunistic infections, or had failed prior treatment. Seven patients (23%) achieved complete remission, 19 (61%) partial remission, and five (61%) no response. With follow-up time to 24 months, the median response duration is eight months. The projected median survival for all patients treated with ABV is nine months. Both regimens were well tolerated, with an overall response rate of 76% for etoposide and 84% for ABV. However, while successfully treating the Kaposi's sarcoma, the underlying immune deficiency in these patients has persisted. Future treatments of Kaposi's sarcoma will need to focus on reversing the underlying immune incompetence as well as controlling the malignant manifestations of Kaposi's sarcoma arising in relation to the acquired immune deficiency syndrome.

scholarly journals Phase II Trial of Imatinib in AIDS-Associated Kaposi's Sarcoma: AIDS Malignancy Consortium Protocol 042

2014 ◽  
Vol 32 (5) ◽  
pp. 402-408 ◽  
Author(s):  
Henry B. Koon ◽  
Susan E. Krown ◽  
Jeannette Y. Lee ◽  
Kord Honda ◽  
Suthee Rapisuwon ◽  
...  
Keyword(s):  
Phase Ii ◽  
Kaposi's Sarcoma ◽  
Alternative Therapy ◽  
Kaposi’S Sarcoma ◽  
Antiretroviral Drugs ◽  
Activating Mutations ◽  
Multicenter Phase ◽  
Predictors Of Response ◽  
Vascular Proliferation

Purpose Kaposi's sarcoma (KS) is a disease of multifocal vascular proliferation that requires infection with KS herpes virus (KSHV/HHV-8). Activation of the c-kit and platelet-derived growth factor (PDGF) receptors by autocrine/paracrine mechanisms follows endothelial cell KSHV infection. In a pilot study, imatinib, a c-kit/PDGF-receptor inhibitor, induced partial regression of AIDS-associated KS (AIDS-KS) in five of 10 patients. Patients and Methods This multicenter phase II study was designed to estimate the response rate to imatinib in AIDS-KS. Secondary objectives included investigation of predictors of response and imatinib pharmacokinetics in patients on antiretrovirals. Patients received imatinib 400 mg/day by mouth for up to 12 months with dose escalation up to 600 mg/day at 3 months if their disease was stable. Results Thirty patients were treated at 12 AIDS Malignancy Consortium sites. Ten patients (33.3%) achieved partial response, six (20%) had stable disease, and seven (23.3%) exhibited KS progression. Nine patients completed 52 weeks of imatinib therapy. The median treatment duration was 22.5 weeks. Only five patients (16.7%) discontinued therapy owing to adverse events. Antiretroviral regimens did not significantly alter imatinib metabolism. Activating mutations in PDGF-R and c-kit were not found at baseline or at disease progression. We found no correlation with response with changes in any of the candidate cytokines. Conclusion Imatinib has activity in AIDS-KS. Pharmacokinetic interactions with antiretroviral drugs did not correlate with toxicity. Thirty percent of patients showed long-term clinical benefit and remained on imatinib for the entire year. These results suggest imatinib is well tolerated and may be an alternative therapy for some patients with AIDS-KS.

scholarly journals Chromosome Binding Site of Latency-Associated Nuclear Antigen of Kaposi's Sarcoma-Associated Herpesvirus Is Essential for Persistent Episome Maintenance and Is Functionally Replaced by Histone H1

2002 ◽  
Vol 76 (24) ◽  
pp. 12917-12924 ◽  
Author(s):  
Hirohiko Shinohara ◽  
Masaya Fukushi ◽  
Masaya Higuchi ◽  
Masayasu Oie ◽  
Osamu Hoshi ◽  
...  
Keyword(s):  
Cell Line ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Histone H1 ◽  
Nuclear Antigen ◽  
Mitotic Chromosomes ◽  
Dividing Cells ◽  
Kaposi’S Sarcoma Associated Herpesvirus ◽  
Chromosome Binding

ABSTRACT Latency-associated nuclear antigen 1 (LANA1) of Kaposi's sarcoma-associated herpesvirus (KSHV; human herpesvirus 8) persistently maintains a plasmid containing the KSHV latent origin of replication (oriP) as a closed circular episome in dividing cells. In this study, we investigated the involvement of chromosome binding activity of LANA1 in persistent episome maintenance. Deletion of the N-terminal 22 amino acids of LANA1 (ΔN-LANA) inhibited the interaction with mitotic chromosomes in a human cell line, and the mutant concomitantly lost activity for the long-term episome maintenance of a plasmid containing viral oriP in a human B-cell line. However, a chimera of ΔN-LANA with histone H1, a cellular chromosome component protein, rescued the association with mitotic chromosomes as well as the long-term episome maintenance of the oriP-containing plasmid. Our results suggest that tethering of KSHV episomes to mitotic chromosomes by LANA1 is crucial in mediating the long-term maintenance of viral episomes in dividing cells.

scholarly journals Trends in Kaposi’s Sarcoma in Miami Beach from 1987 to 2007

ISRN Oncology ◽  
2012 ◽  
Vol 2012 ◽  
pp. 1-10
Author(s):  
Simon B. Zeichner ◽  
Ana L. Ruiz ◽  
Gabriel P. Suciu ◽  
Rachel Lerner Zeichner ◽  
Estelamari Rodriguez
Keyword(s):  
Kaposi's Sarcoma ◽  
Medical Center ◽  
Kaposi’S Sarcoma ◽  
Vascular Tumor ◽  
Low Grade ◽  
Term Survival ◽  
Distant Disease ◽  
Human Herpes Virus 8

Purpose. Kaposi’s sarcoma (KS) is a rare low-grade vascular tumor associated with the human herpes virus 8. By analyzing the epidemiology, staging, and treatment of KS, we hoped to improve the quality of care at our institution. Methods. Review of the Mount Sinai Medical Center tumor registry database in Miami Beach, FL, USA, identified 143 cases of KS between January 1, 1987 and December 31, 2007. Results. The majority of patients were non-Hispanic whites, non smoking males diagnosed between 1987 and 1996. Most of the patients were HIV positive, with an equal percentage diagnosed with local or distant disease. Most patients received no chemotherapy or radiation. There were no significant differences in patient survival based on sex, HIV status, or radiation received. There was a trend toward improved survival among older patients who smoked, received no chemotherapy, and had localized stage at diagnosis. Multivariate analysis revealed that non-Hispanic whites had a significant worse survival than Hispanic whites (HR = 0.55, 95% CI (0.33, 0.90), ). Patients diagnosed between 1987 and 1996 had a worse survival than those between 1997 and 2007 (HR = 0.33 (95% CI 0.19, 0.55), ). Conclusion. This large retrospective study provides further insight into KS. Ethnicity and date of diagnosis are important predictors of long-term survival.

Sign in / Sign up

Export Citation Format

Share Document